Sorrento achieves 100% discharge rate in COVI-MSC study in COVID-19
Apr. 20, 2021 9:20 AM ETSorrento Therapeutics, Inc. (SRNE)SRNEBy: Mamta Mayani, SA News Editor15 Comments
- Sorrento Therapeutics (NASDAQ:SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS).
- This current study (MSC-COV-101) is a single arm study of the safety and preliminary efficacy of COVI-MSCs administered every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion.
- A total of 10 patients were enrolled and all were discharged from the hospital to home within three days of their last COVI-MSC infusion.
- The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.
- Once the full dataset is available, Sorrento will be working with the FDA to plan a placebo-controlled study to support an emergency use authorization submission.
- SRNE shares up 2.1% premarket trading at $7.65.